32 results on '"Zahradova L"'
Search Results
2. Gain 1q21 Versus Velcade- and Thalidomide-Based Regimens: B228
3. Dendritic Cells Immunotherapy: A Phase II Clinical Trial: A518
4. Better Efficacy/Toxicity Ratio of Velcade-Based Regimens: A251
5. High Thrombospondin Level Correlates Closely with Poor Response to Bortezomib Treatment: A185
6. Comparison of whole-body low-dose computed tomography and conventional radiography in the staging of multiple myeloma
7. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse
8. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma – Phase II study results
9. Prognostic significance of morphological assessment of plasma cells in multiple myeloma
10. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation
11. A251 Better Efficacy/Toxicity Ratio of Velcade-Based Regimens
12. A518 Dendritic Cells Immunotherapy: A Phase II Clinical Trial
13. A185 High Thrombospondin Level Correlates Closely with Poor Response to Bortezomib Treatment
14. B228 Gain 1q21 Versus Velcade- and Thalidomide-Based Regimens
15. Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance
16. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.
17. P135 Vaccination of myeloma patients with monoclonal immunoglobulin loaded dendritic cells: preclinical and first clinical results of a phase I/II clinical trial
18. Dendritic cell counts and their subsets during treatment of multiple myeloma
19. CIRCULATING SERUM MIRNA PROFILE IN AL AMYLOIDOSIS
20. Lenalidomide-based regimen proved effective in multisystem Langerhans cell histiocytosis: case report
21. Velcade with possible benefit over the autologous retransplantation in relapsing multiple myeloma
22. Erdheim-Chester disease and our experience with cladribine therapy in two patients
23. GAIN/AMPLIFICATION OF 1Q21 IS THE MOST POWERFUL GENETIC PROGNOSTIC FACTOR FOR PATIENTS TREATED BY AUTOLOGOUS STEM CELL TRANSPLANTATION
24. Isolation and expansion of allogeneic myeloma-specific interferon-gamma producing T cells for adoptive immunotherapy
25. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.
26. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
27. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.
28. Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
29. Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma.
30. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
31. Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
32. Dendritic cell counts and their subsets during treatment of multiple myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.